Title : Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.

Pub. Date : 2021 Mar

PMID : 33222380






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. Crizotinib cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure. Crizotinib cytochrome P450 family 3 subfamily A member 4 Homo sapiens
3 We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure. Crizotinib cytochrome P450 family 3 subfamily A member 4 Homo sapiens